Notice of intent to solicit and negotiate a non-competitive modification for PCV 15 vaccine (VAXNEUVANCE)

The Centers for Disease Control and Prevention (CDC) intends to solicit and negotiate a non-competitive modification to contract number 75D30121D11354, awarded to Merck Sharp & Dohme Corp. (“Merck”) on June 17, 2021.

This notice is provided in accordance with FAR 5.203(a).

This contract is part of CDC’s 2021 Vaccines For Adults (VFA) indefinite-delivery indefinite-quantity contracts. This contract provides for the purchase of standard commercial adult vaccines for the National Center for Immunization and Respiratory Diseases’ (NCIRD) immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and Section 13631of the Omnibus Budget Reconciliation Act of 1993.

This modification will add a maximum of 400,000 doses of the PCV 15 vaccine (VAXNEUVANCE) for adults to the contract following the Advisory Committee on Immunization Practices (ACIP) approval and CDC recommendation in October 2021.

The authority permitting other than full and open competition is FAR 6.302-1, "Only one responsible source and no other supplies or services will satisfy agency requirements." Merck is the only manufacturer with an FDA-approved license for PCV15 at this time.

All responsible sources my submit a capability statement, proposal, or quotation to Joshua Houston, Contract Specialist, at pkf5@cdc.gov, which shall be considered by the agency. The deadline for submissions is November 24, 2021, at 4:30pm Eastern time.

The Government will review any/all information submitted to determine if other responsible sources exist that could provide this requirement. Information received in response to this announcement will be used solely for the purpose of determining whether to conduct a competitive procurement.